Regulation 17 Amendment of regulation 36 (requirement for authorisation to manufacture or import investigational medicinal products)I1F1
United Kingdom
In regulation 36(2), after “marketing authorization” insert “or marketing authorisation issued by the competent authority of an EEA State in accordance with Directive 2001/83/EC”.
Annotations
Textual amendments
- F1
Reg. 17 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 1 para. 3
Commencement
- I1
Reg. 17 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1